No profile data available.
Tango Therapeutics, Inc. (TNGX) is a healthcare company in the medication development research industry, based in Boston, United States, with about 137 full-time employees.
It reported revenue of $62.38 million for fiscal year 2025, up 48.3% from fiscal year 2024, and net income of -$101.59 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0, down 100.0% from a year before. Its market capitalization was $4.01 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
Tango Therapeutics reported $62.38 million in revenue for fiscal year 2025, up 48.3% from $42.07 million in fiscal year 2024. In Q2 2026 revenue was $0.
$4.01 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (medication development research) include AbCellera Biologics Inc. (ABCL), Recursion Pharmaceuticals, Inc. (RXRX), Absci Corporation (ABSI), Evotec SE (EVO).